Carregant...
Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers - WO2010066840
This article evaluates a patent application from Solvay Pharmaceuticals, which claims spiro azepane-oxazolidinones as novel blockers of the voltage-gated potassium channel Kv1.3 for the treatment of diabetes, psoriasis, obesity, transplant rejection and T-cell mediated autoimmune diseases such as rh...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2988097/ https://ncbi.nlm.nih.gov/pubmed/20954790 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/13543776.2010.528392 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|